Please assess the completion status of the following clinical trial:

Trial Title: PALISADE Follow-on Study (ARC004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completion of the ARC003 study~* Written informed consent and/or assent from subjects/guardians as appropriate~* Use of effective birth control by sexually active female subjects of child-bearing potential~Key Exclusion Criteria:~* Early discontinuation from the ARC003 study~* Meets any longitudinally applicable ARC003 study exclusion criteria~* (Group 2 only) Failure to tolerate ≥ 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 study Exit DBPCFC~* Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Placebo Crossovers) (Type: OTHER): Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
- Group 2 (Active Rollovers) (Type: OTHER): Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.

Based on this trial design, predict the completion outcome and termination type (if applicable).